These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2226604)

  • 21. Predicting survival of patients with metastatic renal cell carcinoma.
    Motzer RJ; Mazumdar M
    Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemotherapy of renal cell carcinoma. II. Adriamycin and carboquone combined chemotherapy].
    Osawa T
    Nihon Hinyokika Gakkai Zasshi; 1986 Nov; 77(11):1805-13. PubMed ID: 3573463
    [No Abstract]   [Full Text] [Related]  

  • 23. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
    Mizutani Y; Nakanishi H; Yoshida O; Fukushima M; Bonavida B; Miki T
    Eur J Cancer; 2002 Jan; 38(1):167-76. PubMed ID: 11750847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.
    Droz JP; Theodore C; Ghosn M; Lupera H; Piot G; De Forges A; Klink M; Rouesse J; Amiel JL
    Semin Surg Oncol; 1988; 4(2):97-9. PubMed ID: 3393780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunochemotherapy of metastatic renal cell carcinoma: report of 28 cases.
    Wang HJ; Chen HX; Li HZ
    Chin Med J (Engl); 2005 Jan; 118(2):172-3. PubMed ID: 15667805
    [No Abstract]   [Full Text] [Related]  

  • 26. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
    Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in chemotherapy for renal cell carcinoma.
    Huben RP
    Semin Urol; 1992 Feb; 10(1):16-22. PubMed ID: 1565899
    [No Abstract]   [Full Text] [Related]  

  • 28. Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma.
    Rashid MH; Welsh CT; Bissada NK; Chaudhary UB
    Am J Clin Oncol; 2005 Feb; 28(1):107-8. PubMed ID: 15685046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha.
    Bassukas ID; Hofmockel G; Maurer-Schultze B
    Anticancer Res; 1994; 14(1A):237-45. PubMed ID: 8166454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current status of chemotherapy for renal cell carcinoma].
    Kato T; Sato K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):23-8. PubMed ID: 8291912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
    Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
    Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
    [No Abstract]   [Full Text] [Related]  

  • 32. Cytotoxic chemotherapy for advanced renal cell carcinoma.
    Yagoda A; Petrylak D; Thompson S
    Urol Clin North Am; 1993 May; 20(2):303-21. PubMed ID: 8493752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988.
    Yagoda A
    Prog Clin Biol Res; 1990; 350():227-41. PubMed ID: 2201045
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply from authors re: Camillo Porta, Chiara Paglino. Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studies. Eur Urol 2013;64:71-2: are retrospective data of any value to the specialist treating renal cell carcinoma?
    Weikert S; Grünwald V
    Eur Urol; 2013 Jul; 64(1):72-3. PubMed ID: 23092545
    [No Abstract]   [Full Text] [Related]  

  • 35. Combination therapy in patients with metastatic renal cell carcinoma.
    Escudier BJ
    Clin Adv Hematol Oncol; 2010 Oct; 8(10):665-6. PubMed ID: 21317861
    [No Abstract]   [Full Text] [Related]  

  • 36. [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].
    Rexer H
    Urologe A; 2012 May; 51(5):724-6. PubMed ID: 22576149
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chemotherapy of renal cell carcinoma: experimental study and clinical effect].
    Kanda H; Matsuura T; Akiyama T; Kurita T
    Hinyokika Kiyo; 1988 Nov; 34(11):1879-84. PubMed ID: 3242362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
    Michaelson MD
    Cancer; 2012 Apr; 118(7):1744-6. PubMed ID: 21898374
    [No Abstract]   [Full Text] [Related]  

  • 39. Bevacizumab and everolimus in renal cancer: a rational way forward.
    Stadler WM; Phillips G; George DJ; Halabi S; Small E
    J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
    [No Abstract]   [Full Text] [Related]  

  • 40. Renal cell carcinoma: trying but failing to improve the only curative therapy.
    Acquavella N; Fojo T
    J Immunother; 2013; 36(9):459-61. PubMed ID: 24145356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.